What are the economic implications of the study on cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease? Recent clinical trials found that high-dose statin therapy, compared with conventional-dose statin therapy, reduces the risk of cardiovascular events in patients with acute coronary syndromes (ACS) and stable coronary artery disease (CAD). What does this mean for the business of medicine? Have we established what one day of life is worth, and how do we know when to pay the price?